The First Gene-Edited Cell Replacement Therapy Takes a Step Forward
The first person has received ViaCyte and CRISPR's cell replacement therapy.
Interview with our New Community Screening and Clinical Trial Education Director
Breakthrough T1D has a new community screening and clinical trials education director. She's been a volunteer and now staff since her daughter was diagnosed in 2002.
New Study Shows Kids 1+ Benefit from Artificial Pancreas Technology
A new paper published in the New England Journal of Medicine shows hybrid closed loop systems help children as young as 1 year old achieve better glycemic control.
100 Years, 100 Breakthrough T1D Scientists: Gian Franco Bottazzo, M.D.
In honor of the 100th anniversary of insulin, we are launching “100 Years, 100 Breakthrough T1D Scientists.” The first up: Gian Franco Bottazzo, M.D.
CDC Study: Children Who Have Recovered from COVID-19 May Be at Increased Risk of Diabetes
CDC researchers report an apparent association between pediatric COVID-19 and diabetes diagnoses.
Celebrating the Best of 2021
In 2021, Breakthrough T1D has seen tremendous progress in accelerating cures, improving lives, and advocating for people with type 1 diabetes and their loved ones.
Targeting a New Hormone Helps to Prevent Type 1 Diabetes
A publication authored by Harvard University scientists has found that targeting a new hormone, FABP4, can enhance beta cell function and prevent T1D.
Stem Cell Replacement Therapy: Its Time has Begun
ViaCyte has results on its second stem cell-based technology, providing evidence of stem cells secreting insulin in response to meal consumption.
Progress Toward Cures: Thoughts at Year’s End from Breakthrough T1D’s CEO
Breakthrough T1D CEO Aaron Kowalski, Ph.D., weighs in on the exciting news surrounding stem cell-derived beta cell replacement therapies, now in human clinical trials.
Find Your Something
A resident physician and T1D dad—who also lives with an autoimmune disease—shares his call to action to support Breakthrough T1D and research to cure T1D and improve lives.
